Shots: Kyowa Kirin to receive up front, regulatory & commercial milestones along with royalties and a share of sublicensing income. The company also has an option to retain rights in Japan Cerecor to get exclusive rights for the development, manufacturing and commercialization of CERC-00 for all indications globally including the US, EU and Japan The […]Read More
Shots: Merck KGaA to receive up front, additional regulatory, approval, and sales milestone along with royalties on sales of pimasertib and MSC2015103B. The agreement broadens Day One’s clinical-stage pipeline of targeted cancer therapies with the additions of MEK inhibitors Day One plans to initiate a P-I/II study to evaluate the safety, tolerability, and preliminary efficacy […]Read More
Shots: Beijing Tide to receive up to $517.5M including up front, development, regulatory and sales milestone along with royalties and an option for a revenue-sharing arrangement for certain developed products Graviton to get exclusive development and commercialization rights for TDI01 in all territories (Ex- China) TDI01 is a targeted inhibitor of ROCK2 is currently being […]Read More
Shots: Biomunex to receive up front, development, regulatory & sales milestones, equity investment along with royalties on sales of therapies Onward get the right to pursue development, manufacture & commercialize first-in-class bispecific Ab. The companies will jointly develop the Ab during the preclinical and early clinical program Biomunex is responsible for early preclinical development, while […]Read More
Shots: Atara to receive $60M upfront and ~$610M as development, regulatory & commercialization milestones + tiered royalties on net sales. The collaboration focuses on off-the-shelf T-cell immunotherapy ATA3271 and ATA2271 Atara will lead to IND and process development for ATA3271 and will continue to be responsible for P-I study of ATA2271 while Bayer will be […]Read More
Shots: Dragonfly to receive $475M as up front and is eligible to receive development, regulatory and commercial milestones in addition to 24% royalties on global sales of the therapy. BMS to get exclusive WW license to Dragonfly’s IL-12 investigational immunotherapy program, including its extended half-life cytokine DF6002 BMS will be responsible for the development & […]Read More
Shots: Sangamo to receive $75M upfront within 30 days, $720M milestone payments including up to $420M in development milestones and up to $300M in commercial milestones plus royalties on sales of the product. Additionally, Sangamo to take care of certain research and manufacturing activities funded by Novartis Novartis to get exclusive license rights of ZFP-TFs […]Read More
Shots: Hansa to receive $10M up front, up to $397.5M as development, regulatory & commercial milestones. Hansa will book all sales of therapy and will get royalties on gene therapy sales that arises from treating Ab-positive patients enabled through imlifidase pre-treatment Sarepta get an exclusive WW license to develop and promote imlifidase as a pre-treatment […]Read More
Shots: Alpine to receive $60M up front, ~$805M as option exercise fee, development, regulatory and commercial milestones along with royalties on net sales of ALPN-101 AbbVie to get an option to exclusively license ALPN-101, following exercising the option, AbbVie will conduct all future clinical development, manufacturing, and commercialization activities for ALPN-101 During the option period, […]Read More
Shots: Accent to receive $55M upfront and $1.1B as co-development option and milestone payment, plus royalties and profit split based on the option to co-develop and co-commercialize RMP-targeting therapies for the treatment of cancer in the US Accent will be responsible for research and development activities for a nominated preclinical program through to the end […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
